4-(6-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-N-(2,2,2-trifluoroethyl)thiophene-2-carboxamide

ID: ALA4550262

PubChem CID: 25205097

Max Phase: Preclinical

Molecular Formula: C18H12F3N5OS

Molecular Weight: 403.39

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4cccnc4)cnc23)cs1

Standard InChI:  InChI=1S/C18H12F3N5OS/c19-18(20,21)10-24-17(27)15-4-12(9-28-15)14-7-25-26-8-13(6-23-16(14)26)11-2-1-3-22-5-11/h1-9H,10H2,(H,24,27)

Standard InChI Key:  GDEGOXINVAEAGP-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   17.5655  -17.4582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5655  -18.2754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.2708  -18.6798    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.2708  -17.0455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.9760  -17.4582    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.9760  -18.2764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7542  -18.5293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.2352  -17.8673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7542  -17.2054    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.0083  -19.3106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5279  -19.9717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0082  -20.6329    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   20.7855  -20.3804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7854  -19.5633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.4466  -20.8608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.3612  -21.6735    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.1931  -20.5284    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.8543  -21.0087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6008  -20.6763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.2619  -21.1567    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   23.6862  -19.8636    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   24.3052  -20.2606    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   16.8590  -17.0538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8579  -16.2355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1499  -15.8290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4424  -16.2397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4474  -17.0612    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.1560  -17.4639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  4  2  0
  2  3  2  0
  3  6  1  0
  5  4  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 10  1  0
  7 10  1  0
 13 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 19 21  1  0
 19 22  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 23  1  0
  1 23  1  0
M  END

Associated Targets(Human)

MARK3 Tchem Serine/threonine-protein kinase c-TAK1 (2532 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 403.39Molecular Weight (Monoisotopic): 403.0715AlogP: 3.81#Rotatable Bonds: 4
Polar Surface Area: 72.18Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 13.90CX Basic pKa: 4.55CX LogP: 2.67CX LogD: 2.67
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.56Np Likeness Score: -2.11

References

1. Sloman DL, Noucti N, Altman MD, Chen D, Mislak AC, Szewczak A, Hayashi M, Warren L, Dellovade T, Wu Z, Marcus J, Walker D, Su HP, Edavettal SC, Munshi S, Hutton M, Nuthall H, Stanton MG..  (2016)  Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.,  26  (17): [PMID:27491711] [10.1016/j.bmcl.2016.02.003]

Source